Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1622 • ACR Convergence 2021
Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
Claire Fine¹, Karen Beattie¹, Tania Cellucci², Liane Heale¹, Mark Matsos¹, Stephanie Garner¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult healthcare is a critical time for the wellbeing of patients with chronic illness including rheumatologic disease. Low patient…
Abstract Number: 1735 • ACR Convergence 2021
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Takehiro Nakai¹, Futoshi Iwata¹, Genki Kidoguchi¹, Sho Fukui², Hiroki Ozawa¹, Satoshi Kawaai³, Yukihiko Ikeda¹, Ayako Koido⁴, Masei Suda⁵, Atsushi Nomura⁶, Hiromichi Tamaki¹, Kenichi YAMAGUCHI¹ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St. Luke’s International Hospital, and Center for clinical epidemiology, St. Luke’s International University, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan, ⁵Suwa Central Hospital, Nagano, Japan, ⁶St. Luke's International Hospital, Nagareyama, Japan
Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…
Abstract Number: 1756 • ACR Convergence 2021
Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
April Barnado and Alex Camai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies have investigated treatment patterns and renal outcomes in class V systemic lupus erythematosus (SLE) nephritis patients compared to class III/IV patients. Prior…
Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Louisa-Marie Mockenhaupt¹, Ramona Dolscheid-Pommerich¹, Charlotte Behning¹, Birgit Stoffel-Wagner², Peter Brossart¹ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²University Hospital Bonn, Bonn
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…
Abstract Number: 0134 • ACR Convergence 2021
Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
Sebastian Bruera¹, Xiudong Lei², Xerxes Pundole², Hui Zhao², Sharon Giordano², Surabhi Vinod¹ and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus (SLE) who develop breast cancer (BC), may receive different therapies (e.g. radiation) than women with BC who do not…
Abstract Number: 0333 • ACR Convergence 2021
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese
Chi Chiu Mok¹, Yuen Kwan Chung², Carolyn Lee³, Ling Yin Ho⁴ and Chi Hung To², ¹Tuen Mun Hospital, Hong Kong, China, ²Pok Oi Hospital, Hong Kong, Hong Kong, ³Hospital Authority, Hong Kong, Hong Kong, ⁴Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To validate the 2019 EULAR/ACR classification criteria for SLE in Hong Kong Chinese patients and compare its performance with the 2012 Systemic Lupus International…
Abstract Number: 0351 • ACR Convergence 2021
Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
Javad Wahadat¹, Dieneke Schonenberg-Meinema², Cornelia van Helden-Meeuwsen¹, Sander van Tilburg¹, Noortje Groot³, Ellen Schatorjé⁴, Esther Hoppenreijs⁴, Petra Hissink Muller⁵, Danielle Brinkman⁶, Denis Dvorak⁷, Marleen Verkaaik³, Katerina Bouchalova⁸, Merlijn van den Berg², Sylvia Kamphuis⁹ and Marjan Versnel¹, ¹Erasmus University Medical Center, Rotterdam, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, Netherlands, ³Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Amalia Children's Hospital, Nijmegen, Netherlands, ⁵Willem Alexander Children’s Hospital, Leiden University Medical Center, Leiden, Netherlands, ⁶Willem Alexander Children’s Hospital, Leiden University Medical Center, Leiderdorp, Netherlands, ⁷Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic, ⁸Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic, ⁹Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Clinical phenotyping and predicting treatment responses in Systemic Lupus Erythematosus (SLE) patients is challenging. Extensive blood transcriptional profiling has identified various gene modules that…
Abstract Number: 0535 • ACR Convergence 2021
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Priyal Dave¹, Tiange Dong¹, Andrew Mead¹, Isaac Asante¹, Brandon Ebright¹, Eugene Zhou¹, RIta Li¹, Nicos Petasis¹, William Stohl² and Stan Louie¹, ¹University of Southern California, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…
Abstract Number: 0626 • ACR Convergence 2021
Does Higher Quality of Care in SLE Translate to Better Patient Outcomes?
Shilpa Arora¹, Joel Block¹, Ailda Nika¹, Winston Sequeira¹, Patricia Katz² and Meenakshi Jolly¹, ¹Rush University Medical Center, Chicago, IL, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Quality of care (QOC) as measured by quality indicators (QIs) decreases damage accrual in SLE long term. We aimed to assess if high QOC…
Abstract Number: 0857 • ACR Convergence 2021
Association of Telomere Length with Phenotypic Frailty in Systemic Lupus Erythematosus
Sarah Lieber¹, Robyn Lipschultz¹, Syed Zahid², Mangala Rajan², Myriam Lin¹, Laura Donlin¹, Neal Lue² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Frailty is a novel risk factor for adverse health outcomes in systemic lupus erythematosus (SLE). Although frailly is conceptualized as “accelerated aging,” whether the…
Abstract Number: 0874 • ACR Convergence 2021
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Pankti Mehta, Pratibha Singh and Amita Aggarwal, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: SLE is characterized by increased type I IFN signature in the blood and immune cells. Traditionally, type I IFN signature is measured by gene…
Abstract Number: 0892 • ACR Convergence 2021
Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus
Ruyi Pan¹, Juan Diaz-Martinez², Jessica Gronsbell¹ and Zahi Touma³, ¹University of Toronto, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada
Background/Purpose: The American College of Rheumatology Neuropsychological Battery (ACR-NB) is the standard screening test for cognitive impairment (CI) in systemic lupus erythematosus (SLE). While the…
Abstract Number: 1032 • ACR Convergence 2021
Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity
Tiffany Taylor¹, Christine Anastasiou¹, Stephanie Rush¹, Laura Trupin², Maria Dall'Era³, Patricia Katz¹, Kamil Barbour⁴, Jinoos Yazdany¹ and Milena Gianfrancesco¹, ¹University of California San Francisco, San Francisco, CA, ²UC San Francisco, San Francisco, CA, ³University of California San Francisco, Corte Madera, CA, ⁴Centers for Disease Control, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Data indicate that minority populations are at higher…
Abstract Number: 1178 • ACR Convergence 2021
Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
Mavra Masood, Fnu Nutan, Julia Nunley and Beth Rubinstein, Virginia Commonwealth University, Richmond, VA
Background/Purpose: There is a dearth of resources for medical students on identifying skin findings of autoimmune disorders in skin of color. Considering how several rheumatologic…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].